Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
RELATED PRODUCTS
-
123I MIBG BACON (R&D)
123I MIBG BACON (R&D)It is indicated for: Oncology: a) Scintigraphic localization of tumors originating in tissues that derive embryologically from the neural crest... -
FLPET (R+D)
FLPET (R+D)It is indicated for the detection and evaluation of cell proliferation in lung, breast, colorectal, melanoma, soft tissue sarcoma and primary or metastatic brain tumors. It allows to predict the aggressiveness... -
177Lu DOTATATE (I+D)
177Lu DOTATATE (I+D)It is a radiolabeled somatostatin analog indicated for: - The treatment of gastroenteropancreatic tumors positive for the somatostatin receptor. Neuroendocrine tumors (GEP-NETs), including the foregut...

